NCT00492830View on ClinicalTrials.gov

Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

CancerNeoplasm Metastasis

Interventions

DRUG

TRC093 recombinant humanized IgG1k monoclonal antibody

TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.

Trial Locations (3)

Unknown

Birmingham

Phoenix

Santa Monica

All Listed Sponsors

lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT00492830 - Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter